NEW YORK – Luminex reported after the close of the market on Monday that its first quarter 2020 revenues grew 10 percent year over year, driven in part by molecular diagnostics revenue growth.
For the three months ended March 31, the firm reported revenues of $90.4 million, up from $82.4 million a year ago, which was almost in line with preliminary revenues reported in April and beat the analysts' average estimate of $84.1 million.